Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction.

Inessa NormatovDaniela FluxaJingzhou D WangJacob E OllechGeorge E GulottaShivani PatelMaria A QuinteroBety De la TorreNorma SolisOriana M DamasAmar R DeshpandeDavid H KermanMaria T AbreuDavid T Rubin

Published in: Crohn's & colitis 360 (2021)

Infliximab can be safely and effectively restarted after a drug holiday. We suggest performing TDM with a drug-tolerant assay 1-3 weeks after the first reinduction infusion as a means to identify patients at risk for severe IIR at the second dose.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
ulcerative colitis
emergency department
adverse drug
gestational age
single cell